Real-world impact of bridging therapy on outcomes of ide-cel for myeloma in the U.S. Myeloma Immunotherapy Consortium
2024 · Blood Cancer Journal · 29 citations
https://doi.org/10.1038/s41408-024-00993-0
S
Shebli Atrash
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
335
Papers
2.0K
Citations
21
h-index
41
i10-index
Shebli Atrash is an academic researcher from Advocate Health Care. The author has contributed to research in topics: Multiple Myeloma Research and Treatments & CAR-T cell therapy research & Protein Degradation and Inhibitors. The author has an h-index of 21, co-authored 285 publications.
ORCID: 0000-0003-4547-7534Papers by this author
worksTreatment patterns and effectiveness of patients with multiple myeloma initiating Daratumumab across different lines of therapy: a real-world chart review study
2021 · BMC Cancer · 24 citations
https://doi.org/10.1186/s12885-021-08881-7
Standardizing Clinical Workflow for Assessing Minimal Residual Disease by Flow Cytometry in Multiple Myeloma
2022 · Clinical Lymphoma Myeloma & Leukemia · 12 citations
https://doi.org/10.1016/j.clml.2022.10.008
MRD-driven phase 2 study of daratumumab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma
2024 · Blood Advances · 8 citations
https://doi.org/10.1182/bloodadvances.2024014417
Outcomes of teclistamab in patients with relapsed/refractory multiple myeloma with prior exposure to BCMA-directed therapy: a multicenter study from the U.S. Multiple Myeloma Immunotherapy Consortium
2025 · Blood Cancer Journal · 7 citations
https://doi.org/10.1038/s41408-025-01314-9
Dexamethasone for the management of CRS Related to teclistamab in patients with relapsed/refractory multiple myeloma
2025 · Blood Cancer Journal · 6 citations
https://doi.org/10.1038/s41408-025-01222-y
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat